Sahajanand Medical Technologies IPO

Sahajanand Medical Technologies IPO is set to enter the Indian primary market on October 15, 2026, and will remain open for subscription until October 19, 2026. The mainboard IPO is an Offer for Sale (OFS) of 1,38,22,116 equity shares with a face value of ?1 each, at a price band of ?327–?344 per share. The issue is expected to raise approximately ?475.48 crore, with the shares proposed to be listed on the BSE and NSE. 

Motilal Oswal Investment Advisors, Avendus Capital, HSBC Securities & Capital Markets (India) and Nuvama Wealth Management are managing the issue, while MUFG Intime India is the registrar. The selling shareholders include existing investors and shareholders associated with the company’s promoters. As the IPO is entirely an OFS, the proceeds will go to the selling shareholders rather than to Sahajanand Medical Technologies Ltd. 

About Sahajanand Medical Technologies Ltd.

Founded in 2001 by Dhirajlal Kotadia, Sahajanand Medical Technologies Ltd. develops and manufactures medical devices, primarily for vascular and structural heart interventions. The Company focuses on high-risk Class III and Class C/D medical devices and was the first globally to receive CE certification for a drug-eluting stent (DES) with a biodegradable polymer, known as Infinnium. 

Its product portfolio covers three main categories: vascular intervention products, including coronary stents and balloons; structural heart devices, such as Transcatheter Aortic Valve Implantation (TAVI) systems and occluders; and other products, including renal stents, peripheral drug-coated balloons (DCBs) and selected trading products. 

Sahajanand operates two R&D centres in India and Thailand, supported by 102 professionals, including biomedical engineers and clinical research specialists. Its intellectual property portfolio includes 102 granted patents worldwide, 71 pending patent applications and five design registrations in India. Key products such as Supraflex Cruz, Hydra and Cocoon are supported by 72 clinical studies and are used in more than 76 countries. 

The Company combines direct operations in key European markets, including Germany, Spain, France and the UK, with distributor-led sales and hybrid models in other regions. In India, it serves hospitals such as Narayana Hrudayalaya Limited. Its international presence is supported by clinical expert endorsements, government tenders and partnerships with major Group Purchasing Organizations (GPOs) in Europe. The Company follows a “House of Brands” strategy, marketing its products under established brand names. 

As of March 31, 2025, Sahajanand Medical Technologies had 1,458 full-time employees, 24 consultants and 818 contract-based personnel.